

CLAIMS

1. A liquid tocilizumab formulation stabilized in a phosphate – amino acid dual buffer system having pH of 6.0 to 6.5, wherein the concentration of tocilizumab stabilized is 10 mg/ml to 200 mg/ml, and the amino acid is selected from the group consisting of histidine, glycine and aspartate.
2. The formulation according to the claim 1, is devoid of methionine.
3. The formulation according to the claim 1, further comprises one or more pharmaceutically acceptable excipients, the one or more pharmaceutically excipients are selected from the group consisting of sugar, polyol, arginine, and surfactant.
4. The formulation according to claim 1 or 3, wherein the antibody formulated in the phosphate-amino acid buffer system remains stable and maintains at least 95% of monomeric content and/or contains less than 5% aggregates of the antibody, after storage under one of the following storage conditions:

at 2-8 °C for at least 6 months, or

at 25 °C for at least 6 months, or

at 40 °C for at least 2 weeks.
5. The formulation according to claim 1, has a viscosity of less than 10 cp.